The Institut Mérieux-backed genome engineering platform developer has closed its series E round with commitments from new and existing investors.

Inscripta, a US-based genome engineering technology producer backed by medical technology holding group Institut Mérieux, has raised $150m for the close of its series E round. The round was co-led by investment and financial services group Fidelity and funds and accounts advised by T Rowe Price, with participation from investment bank Morgan Stanley’s Counterpoint Global…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.